Proinflammatory macrophages release CXCL5 to regulate T cell function and limit effects of αPD-1 in steatosis-driven liver cancer
Open Access
- 7 March 2025
- journal article
- Published by Elsevier in JHEP Reports
- Vol. 7 (6) , 101385
Abstract
No abstract availableKeywords
Funding Information
- Wright Family Foundation
- Agilent Technologies Inc
- University of Southern California Norris Comprehensive Cancer Center
- University of Sadat City
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK131492)
- National Institutes of Health
This publication has 43 references indexed in Scilit:
- CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trialInvestigational New Drugs, 2024
- Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancerEuropean Journal of Pharmacology, 2024
- CXCL5 promotes lipotoxicity of hepatocytes through upregulating NLRP3/Caspase-1/IL-1β signaling in Kupffer cells and exacerbates nonalcoholic steatohepatitis in miceInternational Immunopharmacology, 2023
- Therapeutic inhibition of CXCR1/2: where do we stand?Internal and Emergency Medicine, 2023
- Chronic Exposure to Palmitic Acid Down-Regulates AKT in Beta-Cells through Activation of mTORThe American Journal of Pathology, 2022
- Inhibition of Estrogen-Related Receptor α Blocks Liver Steatosis and Steatohepatitis and Attenuates Triglyceride BiosynthesisThe American Journal of Pathology, 2021
- CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic targetCancer Communications, 2020
- Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinomaHepatology, 2012
- CXCL5 Regulates Chemokine Scavenging and Pulmonary Host Defense to Bacterial InfectionImmunity, 2010
- CXC Ligand 5 Is an Adipose-Tissue Derived Factor that Links Obesity to Insulin ResistanceCell Metabolism, 2009